• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    ADMA Biologics (ADMA) Could Be 2% Below Fair Value After Q3 Growth

    Simply Wall St·11/09/2026 16:27:16
    Listen to the news

    ADMA Biologics (ADMA) just delivered third quarter results showing higher sales and net income than a year ago, and management backed its 2026 revenue outlook of at least US$530 million.

    Despite the solid third quarter report, ADMA Biologics has had a mixed run, with the share price falling 28.8% year to date, even after a 28.5% 90 day share price return and a three year total shareholder return of about 3.4x. This points to long term momentum that contrasts with more recent volatility around changing expectations for growth and risk.

    Capitalize on ADMA Biologics' latest earnings momentum by scanning a hand picked 40 high quality undervalued stocks that combine stronger cash flows with sturdier balance sheets.

    ADMA Biologics now trades at what looks like a sharp discount to both analyst targets and one estimate of fair value, even after the recent rebound. Is that a mispricing, or a warning the market is taking seriously?

    Most Popular Narrative: 2% Undervalued

    On the bearish analyst Narrative on Simply Wall St, ADMA Biologics screens with a Fair Value of $13 against a last close of $12.73. This frames a small discount built on slower growth and lower margins, not blue sky forecasts.

    The bearish analysts are assuming ADMA Biologics's revenue will grow by 9.5% annually over the next 3 years. The bearish analysts assume that profit margins will shrink from 35.1% today to 32.5% in 3 years time.

    See why 5 investors see ADMA Biologics as 2% undervalued.

    Result: Fair Value of $13 (UNDERVALUED)

    Still, this cautious ADMA Biologics view could unravel if ASCENIV keeps posting strong double digit growth, or if planned 2026 buybacks lift per share earnings more than expected.

    Find out about the key risks to this ADMA Biologics narrative.

    Next Steps

    Sentiment around ADMA Biologics is split, with clear enthusiasm and clear worries sitting side by side. Act while the data is fresh and compare your own thesis with the 2 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond ADMA Biologics?

    Do not stop with one ticker. Use fresh data, compare multiple opportunities side by side, and let the numbers sharpen your next move instead of guesswork.